Life science investment firm, Medicxi, announced on 7/19/19 that it has closed its Medicxi III fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. The fund was closed after only six weeks. Novartis and JnJ were cornerstone investors. The fund has locations in London, Geneva and Jersey.
Medicxi said that it will invest in early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets. The company's portfolio includes investments in 59 companies are various stages of development.
While it trails the US, Europe's life science investment sector has seen an increase in activity recently. Silicon Valley Investment Bank's recent Healthcare report showed an increase in European investm from $1.8 billion in 2017 to $2.7 billion last year.